DOCSLIB.ORG

2017 Facility and Physician Billing Guide Transcatheter Heart Valve Replacement Technologies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2017 Facility and Physician Billing Guide Transcatheter Heart Valve Replacement Technologies 2017 Facility and Physician Billing Guide Transcatheter Heart Valve Replacement Technologies Physician Inpatient Coding for TAVR Facilities and Physicians use Current Procedural Terminology (CPT1) codes to bill for procedures and services. Each CPT code is assigned unique relative value units (RVUs), which are used to determine payment by the Centers for Medicare and Medicaid Services (CMS). All the CPT codes used to bill for TAVR procedures are listed below. 2017 National Avg. Each Physician CPT Code1, 2 Description Physician Payment Payment 2017 Facility (Final JAN-DEC) (Modifier-62)* RVUs Transcatheter aortic valve replacement 33361 (TAVR/TAVI) with prosthetic valve; $1,421 $888 39.59 percutaneous femoral artery approach Transcatheter aortic valve replacement 33362 (TAVR/TAVI) with prosthetic valve; open $1,550 $969 43.20 femoral artery approach Transcatheter aortic valve replacement 33363 (TAVR/TAVI) with prosthetic valve; open $1,632 $1,020 45.48 axillary artery approach Transcatheter aortic valve replacement 33364 (TAVR/TAVI) with prosthetic valve; open $1,693 $1,058 47.16 iliac artery approach Transcatheter aortic valve replacement 33365 (TAVR/TAVI) with prosthetic valve; trans- $1,862 $1,164 51.88 aortic approach (e.g., median sternotomy, mediastinotomy) Transcatheter aortic valve replacement 33366 (TAVR/TAVI) with prosthetic valve; trans- $2,014 $1,259 56.11 apical exposure (e.g., left thoracotomy) Add-on Codes Transcatheter aortic valve replacement (TAVR/ TAVI) with prosthetic valve; cardio-pulmonary bypass support with percutaneous peripheral 33367+ arterial and venous cannulation (e.g., femoral $653 NA 18.20 vessels) (list separately in addition to code for primary procedure) 2017 National Avg. Each Physician 1, 2 2017 Facility CPT Code Description Payment Physician Payment RVUs (Final JAN-DEC) (Modifier-62)* Transcatheter aortic valve replacement (TAVR/ TAVI) with prosthetic valve; car-diopulmonary bypass support with open peripheral arterial 33368+ and venous cannulation (e.g., femoral, iliac, $780 NA 21.73 axillary vessels) (list separately in addition to code for primary procedure) Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; cardiopulmonary bypass support with 33369+ central arterial and venous cannulation $1,031 NA 28.74 (e.g., aorta, right atrium, pulmonary artery) (list separately in addition to code for primary procedure) Note: *As per the CMS’s NCD for TAVR, TAVR is a two-physician (IC & CS) procedure. Medicare payment for each physician is 62.5% of the established national average payment 8. +33367,33368 and 33369 are add-on codes which does not require modifier 62 hence each physician payment of 62.5% does not apply. Note: Medicare will only pay TAVR physician claims with these CPT codes when billed with the Place of Service (POS) code 21 (Inpatient Hospital), modifier 62 (two surgeons/co-surgeons), modifier Q0 (zero) signifying CED participation (qualifying registry or qualified clinical study) and ICD-10 secondary diagnosis code Z00.6 (Encounter for examination for normal comparison and control in clinical research program) Medicare requires reporting of the Clinical Trial (CT) number on the claim form. For example, the CT number for the TVT Registry is CT01737528 and the PARTNER II Trial is CT01314313. Medicare may return other claims as unprocessable.* Codes 33361-33369 have a 0 day global period; Codes 33361, 33362, 33363, 33364, 33365, 33366, 33367, 33368 and 33369 do not include cardiac catheterization [93451-93572] when performed at the time of the procedure for diagnostic purposes prior to aortic valve replacement. Codes 33361, 33362, 33363, 33364, 33365, 33366, 33367, 33368 and 33369 include all other catheterization[s], temporary pacing, intraprocedural contrast injection[s], fluoroscopic radiological supervision and interpretation, and imaging guidance, which are not reported separately when performed to complete the aortic valve procedure. Additional Notes1 33361-33369 Transcatheter Aortic Valve Replacement Includes: Access and Implantation of the aortic valve (33361-33366) Access sheath placement Advancement of valve delivery system Arteriotomy closure Balloon aortic valvuloplasty Cardiac or open arterial approach Deployment of valve Percutaneous access Temporary pacemaker Valve repositioning when necessary Radiology procedures: Angiography during and after procedure Assessment of access site for closure Documentation of completion of the intervention Guidances for valve placement Supervision and interpretation Excludes: Percutaneous coronary interventional procedures Transvascular ventricular support (33967, 33970, 33973, 33975-33976, 33990-33993, 33999) Code also add-on codes for cardiopulmonary bypass, when appropriate (33367-33369) Code also cardiac catheterization services for purposes other than TAVR/TAVI Code also diagnostic coronary angiography at the same time as TAVR/TAVI when: A previous study is available, but documentation states the patient’s condition has changed since the previous study, visualization of the anatomy/pathology is inadequate, or a change occurs during the procedure warranting additional evaluation of an area outside the current target area No previous catheter-based coronary angiography study is available, and a full diagnostic study is performed, with the decision to perform the intervention based on that study Code also modifier 59 when diagnostic coronary angiography procedures are performed as separate and distinct procedural services on the same day or session as TAVR/TAVI Code also modifier 62 as well as al TAVI/TAVR procedures require the work of two physicians Do not report separately when included in the TAVR/TAVI service (93452-93453, 93458-93461, 933567) Hospital Inpatient Diagnosis and Procedure Coding Medicare inpatient hospital reimbursement is based upon the Medicare Severity Diagnostic-Related Group (MS-DRG) classification system, which assigns MS-DRGs based on ICD-9-CM diagnosis and procedure codes. The following codes generally describe diagnosis and procedures associated with the use of the Edwards SAPIEN 3 transcatheter heart valve. ICD-9-CM3 ICD-10-CM Diagnosis Description Code (effective Description Code Oct. 1st, 2015) 424.1 Aortic valve disorders I35.0 Nonrheumatic aortic (valve) stenosis ICD-9-CM3 ICD-10-CM Diagnosis Description Code (effective Description Code Oct. 1st, 2015) Replacement of Aortic Valve with 35.05 Endovascular replacement of aortic valve 02RF38Z Zooplastic Tissue, Percutaneous Approach Replacement of Aortic Valve with Zooplastic 35.06 Transapical replacement of aortic valve 02RF38H Tissue, Transapical, Percutaneous Approach Pursuant to the final rule for the FY 2015 hospital Inpatient Prospective Payment System (IPPS), CMS created new MS-DRGs for endovascular cardiac MS-DRG5 Description FY 2017 FY 2017 National FY 2017 Geometric Relative Weight Average Payment7 Mean-LOS 266 Endovascular Cardiac Valve 8.3933 $50,053 6.3 Replacement with MCC Endovascular Cardiac Valve 267 6.4720 $38,595 3.7 Replacement without MCC Note: Medicare will only pay TAVR facility claims with these ICD-10-CM codes when billed with the ICD-10 secondary diagnosis code Z00.6 (Encounter for examination for normal comparison and control in clinical research program) and condition code 30 (qualifying clinical trial). Medicare will return all other claims as unprocessable. Principal Diagnosis for Valve-in-Valve with the Edwards SAPIEN XT Transcatheter Heart Valve Depending on the circumstances, there are several ICD-10-CM diagnosis codes that could be used as the principal diagnosis when the encounter is specifically for performing a valve-in-valve procedure at a different operative encounter from the prior valve placement. From a coding perspective, the options are following. Scenario ICD-10 Diagnosis Code ICD-10 Code Description If the previously placed valve was malpositioned Displacement of biological heart or became displaced T82.222A valve graft, initial encounter If the previously placed valve developed Stenosis of cardiac prosthetic devices, stenosis prematurely T82.857A implants and grafts, initial encounter If the previously placed valve developed Leakage of biological heart valve regurgitation prematurely T82.223A graft, initial encounter If the previously placed valve developed stenosis or regurgitation as an expected occurrence as it Encounter for adjustment and Z45.09 management of other cardiac device degenerates toward valve end-of-life Reimbursement Hotline: 1-800-471-9387 Disclaimer Reimbursement information provided by Edwards Lifesciences is gathered from third-party sources and is presented for informational purposes only. Edwards makes no representation, warranty or guarantee as to the timeliness, accuracy or completeness of the information and such information is not, and should not be construed as reimbursement, coding or legal advice. Any and all references to reimbursement codes are provided as examples only and are not intended to be a recommendation or advice as to the appropriate code for the a particular patient, diagnosis, product or procedure or a guarantee or promise of coverage or payment, nor does Edwards Lifesciences warranty that codes listed are appropriate in all related clinical scenarios. It is the responsibility of the provider to determine if coverage exists and what requirements are necessary for submitting a proper claim for reimbursement to a health plan or payer, including the appropriate code(s) for products provided or services rendered. Laws, regulations, and payer policies
Load more

Recommended publications
  • Minimally Invasive Superficial Femoral Artery Endarterectomy: Early Experience with a Modified Technique
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Eur J Vasc Endovasc Surg 16, 254-258 (1998) ENDOVASCULAR AND SURGICAL TECHNIQUES Minimally Invasive Superficial Femoral Artery Endarterectomy: Early Experience with a Modified Technique M. S. Whiteley 1, T. R. Magee 1, E. P. H. Torrie 2 and R. B. Galland* Department of ~Surgery and 2Radiology, Royal Berkshire Hospital, London Road, Reading, U.K. Objectives: To describe our experience of a modified technique for carrying out remote endarterectomy for superficial femoral artery occlusive disease. Methods: A 4-French arterial dilator is inserted using a Smart needle into the popliteal artery below the occlusion. A remote endarterectomy is carried out through an arteriotomy in the proximal superficial femoral artery. The atheroma is cut distal to the lower extent of disease using a Moll ring cutter. The lower flap of atheroma is secured with an intraluminaI stent inserted from the arteriotomy in the superficial femoral artery. The arteriotomy is extended into the common femoral artery and closed with a vein patch. Results: The procedure was completed in 21 of 26 limbs. In 18 cases the superficial femoral artery remained patent at 30 days. Of the 21 cases all but four stayed in hospital for one night. A successful femoropopliteal bypass was carried out in the five patients in whom the procedure was not completed. Conclusion: Insertion of the dilator into the popliteal artery distal to the occlusion before carrying out the remote endarterectomy has two advantages. Firstly, the stent insertion is carried out in the correct plane and prevents dissection of the distal cut atheroma when attempting to pass the guidewire from above.
    [Show full text]
  • Targeting Endothelial Kruppel-Like Factor 2 (KLF2) in Arteriovenous
    Targeting Endothelial Krüppel-like Factor 2 (KLF2) in Arteriovenous Fistula Maturation Failure A dissertation submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY (Ph.D.) in the Biomedical Engineering Program Department of Biomedical Engineering College of Engineering and Applied Science 2018 by Keith Louis Saum B.S., Wright State University, 2012 Dissertation Committee: Albert Phillip Owens III, Ph.D. (Committee Chair) Begona Campos-Naciff, Ph.D Christy Holland, Ph.D. Daria Narmoneva, Ph.D. Prabir Roy-Chaudhury, M.D., Ph.D Charuhas Thakar, M.D. Abstract The arteriovenous fistula (AVF) is the preferred form of vascular access for hemodialysis. However, 25-60% of AVFs fail to mature to a state suitable for clinical use, resulting in significant morbidity, mortality, and cost for end-stage renal disease (ESRD) patients. AVF maturation failure is recognized to result from changes in local hemodynamics following fistula creation which lead to venous stenosis and thrombosis. In particular, abnormal wall shear stress (WSS) is thought to be a key stimulus which alters endothelial function and promotes AVF failure. In recent years, the transcription factor Krüppel-like factor-2 (KLF2) has emerged as a key regulator of endothelial function, and reduced KLF2 expression has been shown to correlate with disturbed WSS and AVF failure. Given KLF2’s importance in regulating endothelial function, the objective of this dissertation was to investigate how KLF2 expression is regulated by the hemodynamic and uremic stimuli within AVFs and determine if loss of endothelial KLF2 is responsible for impaired endothelial function.
    [Show full text]
  • Transpulmonary Closure of Giant Persistent Ductus Arteriosus Under Cardiopulmonary Bypass and Normothermic Cardioplegia
    Published online: 2019-11-25 THIEME 36 TranspulmonaryPoint of Technique Closure of Giant Persistent Ductus Arteriosus Chowdhury et al. Transpulmonary Closure of Giant Persistent Ductus Arteriosus under Cardiopulmonary Bypass and Normothermic Cardioplegia Ujjwal K. Chowdhury1 Sukhjeet Singh1 Niwin George1 Lakshmi Kumari Sankhyan1 Poonam Malhotra Kapoor2 1Department of Cardiothoracic and Vascular Surgery, All India Address for correspondence Ujjwal K. Chowdhury, MCh, Institute of Medical Sciences, New Delhi, India Department of Cardiothoracic and Vascular Surgery, All 2Department of Cardiac Anaesthesia, All India Institute of Medical India Institute of Medical Sciences, New Delhi 110029, India Sciences, New Delhi, India (e-mail: [email protected]). J Card Crit Care TSS 2020;3:36–38 Abstract A 25-year-old female patient with a giant, short, calcified, hypertensive, window duc- tus arteriosus underwent successful closure via transpulmonary approach under nor- Keywords mothermic cardiopulmonary bypass without circulatory arrest using a Foley catheter ► giant ductus for temporary occlusion. arteriosus ► adult ductus ► cardiopulmonary bypass ► transpulmonary closure ► calcified ductus Introduction chylothorax, or recanalization. Postoperative computerized tomographic angiography revealed complete ductal inter‑ Despite 80 years of experience, correction of persistent duc‑ ruption with no residual shunt or ductal aneurysm (►Fig. 3). tus arteriosus remains a surgical challenge in the subset of 1. Primary median sternotomy is performed. patients
    [Show full text]
  • V5 Data Dictionary Supplement with Pending Data Element Updates
    V5 Data Dictionary Supplement with Pending Data Element Updates The mission of the NCDR® is to improve the quality of cardiovascular patient CathPCI by providing information, knowledge and tools; implementing quality initiatives; and supporting research that improves patient CathPCI and outcomes. The NCDR® is an initiative of the American College of Cardiology Foundation, with partnering support from the Society for Cardiovascular Angiography and Interventions for the CathPCI Registry. CONFIDENTIALITY NOTICE This document contains information confidential and proprietary to the American College of Cardiology Foundation. This document is intended to be a confidential communication between ACCF and participants of the CathPCI Registry and may involve information or material that may not be used, disclosed or reproduced without the written authorization of the ACCF. Those so authorized may only use this information for a purpose consistent with the authorization. Reproduction of any section of this document with permission must include this notice. Table of Contents Section G. Cath Lab Visit Seq#7400 Indications for Cath Lab Visit....................................................................................Page 3 Seq#7405 Chest Pain Symptom Assessment…………………………………….…………………………………..Page 5 Section I. PCI Procedure Seq#7825 Percutaneous Coronary Intervention Indication......................................................Page 6 Review of Cath Lab Indications & PCI Indications…………………………………………….….….……….…. Page 8 Section K. Intra and Post-Procedure
    [Show full text]
  • NCDR® Cathpci Registry® V4.4 Coder's Data Dictionary
    NCDR® CathPCI Registry® v4.4 Coder's Data Dictionary A. Demographics Seq. #: 2000 Name: Last Name Coding Instructions: Indicate the patient's last name. Hyphenated names should be recorded with a hyphen. Target Value: The value on arrival at this facility Selections: (none) Supporting Definitions: (none) Seq. #: 2010 Name: First Name Coding Instructions: Indicate the patient's first name. Target Value: The value on arrival at this facility Selections: (none) Supporting Definitions: (none) Seq. #: 2020 Name: Middle Name Coding Instructions: Indicate the patient's middle name. Note(s): It is acceptable to specify the patient's middle initial. If the patient does not have a middle name, leave field blank. If the patient has multiple middle names, enter all of the middle names sequentially. Target Value: The value on arrival at this facility Selections: (none) Supporting Definitions: (none) Seq. #: 2030 Name: SSN Coding Instructions: Indicate the patient's United States Social Security Number (SSN). Note(s): If the patient does not have a US Social Security Number (SSN), leave blank and check 'SSN NA'. Target Value: The value on arrival at this facility Selections: (none) Supporting Definitions: (none) Seq. #: 2031 Name: SSN N/A Coding Instructions: Indicate if the patient does not have a United States Social Security Number(SSN). Target Value: The value on arrival at this facility Selections: Selection Text Definition No Yes Supporting Definitions: (none) Effective for Patient Discharges April 1, 2011 © 2008, American College of Cardiology Foundation 1/5/2011 3:12:46 PM Page 1 of 82 NCDR® CathPCI Registry® v4.4 Coder's Data Dictionary A.
    [Show full text]
  • PBA Thrombo-Embolectomy
    Vascular Surgery PBA: Thrombo-Embolectomy Trainee: Assessor: Date: Assessor's Position*: Email (institutional): GMC No: Duration of procedure (mins): Duration of assessment period (mins): Hospital: Operation more difficult than usual? Yes / No (If yes, state [ ] Tick this box if this PBA was performed in a Simulated reason) setting. [ ]Basic (e.g. straightforward brachial embolectomy) Complexity (tick which applies, if any) [ ]Intermediate (e.g. thrombolyis for residual thrombo-embolus) [ ]Advanced (e.g. popliteal embolectomy and vein patch repair) [ ]Involved vessel: (circle one) Femoral - Popliteal - Brachial - Subtype (tick which applies, if any) Other * Assessors are normally consultants (senior trainees may be assessors depending upon their training level and the complexity of the procedure) IMPORTANT: The trainee should explain what he/she intends to do throughout the procedure. The Assessor should provide verbal prompts if required, and intervene if patient safety is at risk. Rating: N = Not observed or not appropriate D = Development required S = Satisfactory standard for CCT (no prompting or intervention required) Rating Competencies and Definitions Comments N/D/S I. Consent Demonstrates sound knowledge of indications and contraindications including C1 alternatives to surgery Demonstrates awareness of sequelae of operative or non operative C2 management C3 Demonstrates sound knowledge of complications of surgery Explains the procedure to the patient / relatives / carers and checks C4 understanding C5 Explains likely outcome and time to recovery and checks understanding II. Pre operation planning Demonstrates recognition of anatomical and pathological abnormalities (and PL1 relevant co-morbidities) and selects appropriate operative strategies / techniques to deal with these Demonstrates ability to make reasoned choice of appropriate equipment, PL2 materials or devices (if any) taking into account appropriate investigations e.g.
    [Show full text]
  • 2018 CPT Code Update: Interventional & Diagnostic Radiology
    11/30/2017 2018 CPT Code Update: Interventional & Diagnostic Radiology Stacie L. Buck, RHIA, CCS‐P, RCC, CIRCC, AAPC Fellow President & Senior Consultant RadRx December 5, 2017 RadRx “Your Prescription for Accurate Coding & Reimbursement” Speaker Stacie L. Buck, RHIA, CCS‐P, RCC, CIRCC • Stacie L. Buck, RHIA, CCS‐P, RCC, CIRCC, RCC is President & Senior Consultant at RadRx in Stuart, FL. Stacie is a nationally sought out speaker who provides consulting services to providers of diagnostic and interventional radiology services. She is the author of the book Cracking the IR Code: Your Comprehensive Guide to Mastering Interventional Radiology Coding and creator of Mastering Interventional Radiology & Cardiology Online Education Program. Stac ie has 25 years experience in healthcare, 17 of which she has spent working in radiology. She is a nationally Contact sought out speaker who has presented Email: [email protected] well over 200 coding seminars. Website: www.radrx.com RadRx “Your Prescription for Accurate Coding & Reimbursement” 2 1 11/30/2017 DIAGNOSTIC RADIOLOGY RadRx “Your Prescription for Accurate Coding & Reimbursement” Chest X‐Rays • 71045 Radiologic examination chest; single view – 71010 (frontal), 71015(stereo frontal), 71035 (special views) • 71046 Radiologic examination chest; two views – 71020 (AP & Lat), 71035 (special views) • 71047 Radiologic examination chest; three views – 71021 (2 v w/ apical lordotic), 71022 (2v w/ oblique), 71035 ((pspecial views) • 71048 Radiologic examination chest; 4 or more views – 71030 (min 4 v), 71034 (min 4 v w/ fluoro), 71035 (special views) RadRx “Your Prescription for Accurate Coding & Reimbursement” Copyright 2017. RadRx all rights reserved. Unauthorized distribution is prohibited. 2 11/30/2017 Abdominal X‐Rays • 74018 Radiologic examination abdomen; 1 view – 74000 (AP) • 74019 Radiologic examination abdomen; 2 views – 74010 (AP & addl oblique/cone) • 74021 Radiologic examination abdomen; 3 or more views – 74020 (complete inc.
    [Show full text]
  • Non-Sternotomy Minimally Invasive Pulmonary Embolectomy
    Lessons learned on a new procedure: Non-Sternotomy Minimally Invasive Pulmonary Embolectomy Danuel Laan1, Edwyn Assaf2, John Fallon3, and Omar Lattouf4 1Emory University 2American University of Beirut 3Emory University Hospital 4Emory University School of Medicine July 16, 2020 Abstract Since publication of our initial experience with non-sternotomy minimally invasive pulmonary embolectomy (MIPE) via a left mini thoracotomy, we have expanded our experience, refined the operation and streamlined the post-operative management of patients. Our initial publication described three patients who underwent MIPE.1 We described our technique which included peripheral cardiopulmonary bypass (CPB) via femoral arterial and venous cannulation, left sided 5cm anterior thoracotomy in the 3rd intercostal space, identification and incision of the main pulmonary artery distal to the pulmonic valve, extraction of clot with subsequent primary closure of the pulmonary artery, and use of a 5mm, 30 degree laparoscope as an adjunct to assess clearance of the pulmonary artery.2 The patients included in this series had no post-operative complications, had a mean hospital length of stay of three days with mid-term follow-up up to 8-months revealing no untoward complications of the procedure. With early success of the MIPE at our institution, we began employing it preferentially over sternotomy with central CPB and pulmonary embolectomy. Since initial publication of our results, we have performed the MIPE in two additional patients with excellent outcomes. We herein present augmentations we’ve made to the procedure with a case-presentation which highlights these adaptations. 7/15/20 Dear Editor(s) and Reviewers, Journal of Cardiac Surgery Please find within our manuscript entitled ‘Lessons Learned on a New Procedure: Non-Sternotomy Minimally Invasive Pulmonary Embolectomy .’ Type of paper: Original Article Conflicts of Interest and Source of Funding: The authors have no relevant financial disclosures.
    [Show full text]
  • Interventional Radiology Coding Case Studies Prepared by Stacie L. Buck
    Interventional Radiology Coding Case Studies Prepared by Stacie L. Buck, RHIA, CCS-P, RCC, CIRCC, AAPC Fellow President & Senior Consultant Week of September 3, 2018 Pulmonary Angiogram & Phrenic Angiogram CLINICAL HISTORY: The patient is a 50-year-old female with incidentally identified asymptomatic vascular anomaly in the right lower lobe, who presents to interventional radiology for diagnostic arteriograms from the systemic arterial and pulmonary arterial systems. The patient has a positive agitated saline echocardiogram. Pulmonary arteriovenous malformation is suspected. Of note, the patient also has a small patent foramen ovale. PROCEDURES: 1. Real-time ultrasound-guided access into the right common femoral artery after documentation of selected vessel patency and permanent imaging storing in the patient records. 2. Right common femoral arteriogram. 3. Right phrenic arteriogram. 4. Real-time ultrasound guided access into the right common femoral vein after documentation of selected vessel patency and permanent imaging storing in the patient records. 5. Right pulmonary arteriogram. 6. Closure of the right common femoral arteriotomy with a Star close device. 7. Closure of the left common femoral venotomy with manual pressure. Pre-Procedure Diagnosis: RLL PULMONARY VASCULAR ABNORMALITY Post-Procedure Diagnosis: RLL PULMONARY VASCULAR ABNORMALITY MONITORING: The procedure was performed with general anesthesia. MEDICATIONS: Refer to anesthesia notes for details. 1O ml of 1 % Lidocaine SQ. 1 g Ancef IV CONTRAST: 50 ml Omnipaque 300. FLUOROSCOPY TIME: 33. DAP: 13842 uGym2. RadRx “Your Prescription for Accurate Coding & Reimbursement” Copyright 2018. All Rights Reserved. www.radrx.com Distribution of this document is strictly prohibited. The content is created exclusively for those individuals who have a paid subscription to the RadRx Weekly Interventional Case Studies.
    [Show full text]
  • Draft 2016 Vascular
    2016 Cordis® Cardiac & Vascular Procedures Reimbursement Guide ® Table of Contents Description Page Hospital Inpatient Issues 2 Hospital Inpatient Coding 4 Hospital Inpatient Reimbursement 9 Hospital Outpatient Issues 13 Hospital Outpatient Reimbursement 15 Ambulatory Surgery Center and Independent Diagnostic Testing Facility Issues 20 Physician Reimbursement Issues 24 Bundling – NCCI and OCE Issues 25 CPT® Coding Updates in Recent Years 26 Modifiers 31 Disclaimer – The information contained in this guide has been compiled by a third-party organization from published sources and is provided for use as a reference for healthcare provider. The information is to the best of our knowledge true and accurate at the time of publication and may be subject to change without notice as a result of changing laws, regulations, local policies and rules. Healthcare providers are ultimately responsible for determining appropriate practices for services provided, procedures performed, and reimbursement sought including, but not limited to, medical necessity determination and documentation requirements, coding, coverage policy, billing, and payment for individual patients. Providers should consult each payor organization with regard to local reimbursement policies and requirements for billing. The information contained in this document is provided for information purposes only and represents no statement, promise or guarantee by Cordis Corporation concerning levels of reimbursement, payment, or charge. Similarly, all codes are provided for information purposes only and represent no statement, promise or guarantee by Cordis Corporation that these codes will be appropriate for any procedure using Cordis® products or that reimbursement will be made. It is important to research coverage and payment for procedures on a payer-specific basis as coverage policies and guidelines vary by payer.
    [Show full text]
  • Surgical Treatment of CTEPH
    ERJ Express. Published on November 8, 2012 as doi: 10.1183/09031936.00058112 Surgical treatment of CTEPH Proceedings from the International Scientific and Educational Workshop in CTEPH, Cambridge, UK, 27th & 28th June 2011 DP Jenkins1, M Madani2, E Mayer3, K Kerr2, N Kim2, W Klepetko4, M Morsolini5,P Dartevelle6 1 Papworth Hospital, Cambridge, UK, 2 University of California at San Diego, USA, 3 Kerckhoff center, Bad Nauheim, Germany, 4 University of Vienna, Austria, 5 San Matteo Hospital, Pavia, Italy, 6 Hopital Antoine Beclere, Paris, France. Word count: 4517 Author for correspondence DP Jenkins Papworth hospital Cambridge CB23 3RE UK Tel +44 (0)1480 364806/7 Facimile +44 (0)1480 364907 Email [email protected] Copyright 2012 by the European Respiratory Society. Abstract It is likely that chronic thromboembolic pulmonary hypertension (CTEPH) is more prevalent than currently recognised. Imaging studies are fundamental to decision making with respect to operability. All patients with suspected CTEPH should be referred to an experienced surgical centre. Currently there is no risk scoring stratification system to guide operability assessment and it is predominantly based on surgical experience. The aim of the pulmonary endarterectomy (PEA) operation is the removal of obstructive material to immediately reduce pulmonary vascular resistance (PVR). PEA affords the best chance of cure, but is difficult to perfect. Recognition and clearance of, especially distal segmental and subsegmental disease is the main problem. The basic surgical techniques include: median sternotomy incision, cardiopulmonary bypass, arteriotomy incisions within pericardium and a true endarterectomy with meticulous full distal dissection. Deep hypothermic circulatory arrest (DHCA) is recommended as the best means of reducing blood flow in the pulmonary artery to allow a clear field for dissection.
    [Show full text]
  • SUMMARY REPORT ICD-9-CM Coordination and Maintenance
    SUMMARY REPORT ICD-9-CM Coordination and Maintenance Committee Volume 3, Procedures December 4, 1997 Patricia E. Brooks, Co-Chairperson Centers for Medicare and Medicaid Services INTRODUCTIONS AND ANNOUNCEMENTS The members of the Committee and the participants introduced themselves. It was stated that the purpose of the Committee is to provide a public forum to discuss proposed changes to the ICD-9-CM coding system. The first day of the meeting, December 4, 1997, was conducted by the Centers for Medicare and Medicaid Services (CMS) which is responsible for procedures. The second day, December 5, 1997, was conducted by the National Center for Health Statistics (NCHS) which is responsible for diagnoses. NCHS prepares a separate summary of the meeting along with handouts on diagnoses issues. TIME FRAMES FOR CODING REVISIONS It was explained that revisions to ICD-9-CM are made once a year, effective October 1 of each year. Major changes in those time frames were announced in the Prospective Payment System, Final Notice, published August 29, 1997. (Volume 62, Number 168, page 45970). Beginning with the FY 1999 update, the hospital prospective payment updates must be published as a proposed rule by April 1 and as a final rule by August 1 of each year. Therefore decisions on final ICD-9-CM code revisions must be made one month earlier this year. This allows for very little time after the December 1997 meeting for comments. Participants were urged to send any written or electronic comments as soon as possible and by at least early January. Any complicated suggestions that cannot be easily resolved will therefore be carried over for the FY 2000 updates.
    [Show full text]